Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.76 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.76 |
| ▸ | LMNA | P02545 | 5/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21669903 | 1.00 | MAPT (0.77) | MAPTAKR1C3AKR1C1LMNASMN1; SMN2 | |
| SCHEMBL610121 | 1.00 | MAPT (0.77) | MAPTAKR1C3AKR1C1LMNASMN1; SMN2 | |
| SCHEMBL5243601 | 0.92 | AKR1C3 (0.90) | MAPTAKR1C3AKR1C1LMNASMN1; SMN2 | |
| SCHEMBL19392388 | 0.90 | MAPT (0.80) | MAPTAKR1C3AKR1C1LMNASMN1; SMN2 | |
| SCHEMBL12793334 | 0.90 | MAPT (0.80) | MAPTAKR1C3AKR1C1LMNASMN1; SMN2 | |
| SCHEMBL25293495 | 0.90 | MAPT (0.80) | MAPTAKR1C3AKR1C1LMNASMN1; SMN2 | |
| SCHEMBL21670254 | 0.88 | LMNA (0.70) | MAPTAKR1C3AKR1C1LMNASMN1; SMN2 | |
| SCHEMBL21670261 | 0.88 | LMNA (0.70) | MAPTAKR1C3AKR1C1LMNASMN1; SMN2 | |
| SCHEMBL21670262 | 0.88 | LMNA (0.70) | MAPTAKR1C3AKR1C1LMNASMN1; SMN2 | |
| SCHEMBL25288749 | 0.87 | MAPT (0.76) | MAPTAKR1C3AKR1C1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758882-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-23 | — | — | EP | disclosed |
| CN-101001850-A | Amido compounds and their use as pharmaceuticals | INCYTE CORP (US) | 2007-07-18 | — | — | CN | disclosed |
| EP-1758882-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006012173-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050288317-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288317-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | MAPT 3609/4885AKR1C3 43/4885AKR1C1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.